Increase in prevalence of pneumonia across the globe, upsurge in government focus on immunization programs for pneumonia and rise in focus for novel pneumococcal vaccines fuel the growth of the global pneumonia vaccine market.
According to the report published by Allied Market Research, the global pneumonia vaccine market was estimated at $7.08 billion in 2017 and is expected to reach $10.21 billion by 2025, growing at a CAGR of 5.0% from 2018 to 2025. The report offers a detailed analysis of the top winning strategies, top investment pockets, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.
Rise in prevalence of pneumonia across the globe, increase in government focus on immunization programs for pneumonia and surge in focus for novel pneumococcal vaccines propel the growth of the global pneumonia vaccine market. On the other hand, longer timelines required for pneumonia vaccine production and high cost associated with the development of such vaccines hamper the growth to some extent. However, development of protein-based combination pneumococcal vaccines is expected to create an array of opportunities in the near future.
Download Sample Copy of this Report @ https://www.alliedmarketresearch.com/request-sample/2730
The pneumococcal conjugate vaccine (PCV) segment to maintain its dominance-
Based on vaccine type, the pneumococcal conjugate vaccine (PCV) segment contributed to 89% of the total market share in 2017 and is expected to dominate through 2018–2025. The pneumococcal polysaccharide vaccine (PPV) segment, on the other hand, would register the fastest CAGR of 5.4% during the study period.
The Prevnar 13 segment to lead the trail by 2025-
Based on product type, the Prevnar 13 segment held the major share in 2017, accounting for nearly four-fifths of the total market. The segment would also grow at the fastest CAGR of 5.1% during the forecast period.
North America generated the lion’s share in terms of revenue-
Based on geography, North America held more than half of the market share in 2017 and is expected to rule the roost throughout 2018–2025. Simultaneously, Asia Pacific would showcase the fastest CAGR of 6.6% during the estimated period.
Check available discounts on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/2730
The key players analyzed in the report includes:
- Merck & Co., Inc
- Glaxosmithkline plc
- Walvax Biotechnology Co
- Panacea Biotec Limited
- Pfizer Inc
These players have embraced high-end market strategies such as partnerships, collaboration, mergers & acquisitions, and new product launch to heighten their stand in the industry..
Pneumonia Vaccine Market Key Findings of the:
- Prevnar 13 vaccine is expected to be the fastest growing product with a CAGR of 5.1%.
- The distribution partner companies held approximately half of the global market share and is expected to remain dominant throughout the forecast period.
- The pneumococcal conjugate vaccine (PCV) segment is expected to grow with a CAGR of 5.1% from 2017 to 2025.
- The private segment held more than threeforth share in the global market and is expected to remain dominant throughout the forecast period.
- Asia-Pacific is expected to be the fastest growing region, registering a CAGR of 6.6% during the forecast period.
Scope of the Report
|Market size available for years||2018-2025|
|Base year considered||2019|
|Forecast units||Value (USD)|
|Segments covered||Type and Product Type|
|Geographies covered||North America, Europe, Asia-Pacific, LAMEA|
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060